You'll hear that pioglitazone (Actos) slows atherosclerosis

May 2008

You'll hear that pioglitazone (Actos) slows atherosclerosis.

Recent evidence suggests less progression of atherosclerosis in type 2 diabetes patients taking pioglitazone compared to glimepiride (Amaryl).

This doesn't seem to be due to pioglitazone's glucose-lowering effect...it might be due to changes in lipids or other factors.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote